Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
METHOHEXITAL SODIUM vs BUCET
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Methohexital sodium is a barbiturate that acts as a GABA-A receptor agonist, enhancing chloride conductance and causing neuronal hyperpolarization. It produces rapid sedation and anesthesia by depressing the central nervous system.
Bucet is a combination of bucetin and acetaminophen. Bucetin is a para-aminophenol derivative with analgesic and antipyretic effects, possibly through inhibition of cyclooxygenase in the central nervous system. Acetaminophen inhibits COX enzymes in the brain, reducing prostaglandin synthesis and fever.
Induction of anesthesia (FDA-approved),Maintenance of anesthesia (as an adjunct) (FDA-approved),Procedural sedation (off-label),Treatment of refractory status epilepticus (off-label)
Management of mild to moderate pain,Reduction of fever
Induction of anesthesia: 1-1.5 mg/kg IV bolus over 15-30 seconds. Maintenance: intermittent IV boluses of 20-40 mg every 4-7 minutes as needed.
Oral: 25-50 mg every 4-6 hours as needed for pain; maximum 200 mg/day.
Terminal elimination half-life is 1.6–4.8 hours (mean ~3.9 hours) in adults. Context: Rapid redistribution shortens clinical duration; elimination half-life is longer in elderly and hepatic impairment.
2-4 hours (terminal); prolonged in renal impairment
Primarily hepatic metabolism via CYP2B6 and other microsomal enzymes; undergoes oxidation and glucuronidation. Active metabolites are minimally important.
Bucetin: Hepatic metabolism via hydroxylation and glucuronidation. Acetaminophen: Hepatic metabolism via glucuronidation, sulfation, and CYP2E1-mediated oxidation to NAPQI.
Renal: <1% unchanged; hepatic metabolism followed by renal excretion of metabolites accounts for >95% of elimination. Fecal: negligible (<1%).
Renal: ~70% unchanged; biliary/fecal: ~30% as metabolites
85–90% bound to albumin.
~85% bound to albumin
2.0–3.0 L/kg; context: High Vd due to extensive tissue distribution, especially to adipose tissue.
0.3-0.5 L/kg; distributes primarily into extracellular fluid
Intramuscular: ~90–100%; Rectal: ~70–80%; Oral: not available (inactive due to first-pass metabolism).
Oral: 75-90%
No specific dose adjustment required for GFR 30-89 m L/min. For GFR <30 m L/min or dialysis: use with caution; consider reduced dose due to potential prolonged effect.
GFR 10-50 m L/min: 50% dose reduction; GFR <10 m L/min: avoid use.
Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce dose by 25-50%. Child-Pugh Class C: use alternative agent or reduce dose by 50% with careful titration.
Child-Pugh A: no adjustment; Child-Pugh B: 50% dose reduction; Child-Pugh C: avoid use.
Induction: 1-2 mg/kg IV bolus. Maintenance: 0.5-1 mg/kg IV bolus as needed. Maximum single dose: 100 mg.
Children 6-12 years: 5 mg/kg/dose every 6 hours as needed; maximum 20 mg/kg/day.
Reduce initial dose by 25-50% (0.5-1 mg/kg IV) and titrate slowly due to increased sensitivity and prolonged recovery.
Start at lowest effective dose (12.5 mg every 6 hours); maximum 150 mg/day due to increased fall risk and renal impairment.
Risk of respiratory depression and apnea; intravenous administration should be performed only by persons trained in the use of general anesthetics and able to maintain a patent airway and support ventilation. Continuous monitoring of respiratory function is required.
No FDA black box warnings for bucet. Acetaminophen component: Risk of severe liver injury at high doses or with alcohol use.
Respiratory depression and apnea,Hypotension and bradycardia,Injection site reactions (thrombophlebitis, necrosis, extravasation),Risk of emergence delirium and postoperative confusion,Laryngospasm and bronchospasm,Accumulation with repeated doses in patients with hepatic or renal impairment
Hepatotoxicity risk with acetaminophen overdose,Avoid alcohol use,Hypersensitivity reactions,Skin reactions (Stevens-Johnson syndrome)
Hypersensitivity to methohexital or other barbiturates,Acute intermittent porphyria or porphyria variegata,Uncontrolled severe hypotension or shock,Status asthmaticus,Severe respiratory insufficiency,Known or suspected massive drug overdose
Severe hepatic impairment,Hypersensitivity to bucetin or acetaminophen
No specific food interactions are documented for methohexital sodium. However, it is recommended to avoid heavy meals immediately before anesthesia to reduce risk of aspiration. Grapefruit juice may theoretically increase barbiturate levels by inhibiting CYP3A4, though clinical significance is unclear. Always follow pre-operative fasting instructions.
No known food interactions. Avoid alcohol as it may increase risk of side effects like dizziness.
Methohexital sodium is a barbiturate anesthetic. Use in the first trimester may be associated with a small increased risk of major malformations based on limited human data; animal studies show developmental toxicity at high doses. In the second and third trimesters, there is a risk of fetal depression and neonatal withdrawal if used chronically near term. Avoid in first trimester if possible; use only if clearly needed.
FDA Pregnancy Category D. First trimester: Increased risk of cardiac malformations and neural tube defects. Second and third trimesters: Risk of premature closure of ductus arteriosus, oligohydramnios, and neonatal renal impairment.
Methohexital enters breast milk in low amounts; the infant dose is estimated at <1% of maternal weight-adjusted dose. M/P ratio is approximately 0.5. Due to potential for neonatal sedation and the drug's short half-life, breastfeeding should be avoided for at least 4-6 hours after maternal administration.
Contraindicated. Excreted in human milk; M/P ratio not established. Potential for serious adverse effects in nursing infant.
Pregnancy may alter pharmacokinetics: increased volume of distribution and clearance may require slightly higher initial doses for induction, but no specific dose adjustment is recommended; titrate to effect. Use lowest effective dose due to potential for fetal depression.
Avoid use during pregnancy. If unavoidable, reduce dose by 50% due to increased clearance and altered protein binding.
METHOHEXITAL SODIUM is an ultra-short-acting barbiturate used for induction of general anesthesia. It has a rapid onset (less than 30 seconds) and short duration (5-10 minutes) due to redistribution. It is highly protein-bound and should be used with caution in patients with hypoalbuminemia. Contraindicated in porphyria. Avoid extravasation as it is a tissue irritant. May cause apnea, laryngospasm, and hypotension. Dose reduction needed in elderly or debilitated patients.
Bucet (bupivacaine hydrochloride and epinephrine) is used for local anesthesia. Epinephrine prolongs anesthetic effect and reduces systemic absorption. Avoid in patients with severe hypertension, hyperthyroidism, or concurrent MAO inhibitors. Monitor for CNS and cardiac toxicity, especially with high doses. Epinephrine concentration is 1:200,000; check for allergy to sulfites (antioxidant).
This medication will cause you to lose consciousness quickly and is only given by a healthcare professional.,You will be closely monitored during and after administration.,You may experience drowsiness, dizziness, or confusion after waking up; do not drive or operate machinery for 24 hours.,Inform your doctor if you have any allergies, porphyria, or liver/kidney disease.,Avoid alcohol and other sedatives for at least 24 hours after receiving this medication.
Do not drive or operate machinery until numbness subsides.,Avoid touching or scratching the numb area to prevent injury.,Report any signs of allergic reaction (rash, swelling, difficulty breathing) or intravenous injection symptoms (rapid heart rate, anxiety, headache).,The numbness will wear off over several hours depending on the dose and site.
"The combination of methohexital, a barbiturate anesthetic, and mesoridazine, a phenothiazine antipsychotic, can lead to additive central nervous system (CNS) depression and respiratory depression due to synergistic pharmacodynamic effects on GABAergic and dopaminergic pathways. This interaction may result in enhanced sedation, hypotension, and increased risk of respiratory arrest, particularly during induction or maintenance of anesthesia. Patients with underlying respiratory or cardiovascular compromise are at heightened risk for severe adverse outcomes."
"Methohexital, a barbiturate anesthetic, induces cytochrome P450 (CYP) 3A4 enzyme activity, accelerating the hepatic metabolism of azelnidipine, a dihydropyridine calcium channel blocker. This results in reduced plasma concentrations and diminished antihypertensive efficacy of azelnidipine, potentially leading to inadequate blood pressure control during concurrent use."
"Concomitant use of Methohexital, a barbiturate anesthetic with central nervous system (CNS) depressant effects, and Guanfacine, an alpha-2 adrenergic agonist with sedative properties, can lead to additive CNS depression. This may result in enhanced sedation, respiratory depression, hypotension, and bradycardia. Patients may experience excessive drowsiness, impaired cognitive and motor function, and increased risk of falls or respiratory compromise, particularly during anesthesia induction or recovery."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about METHOHEXITAL SODIUM vs BUCET, answered by our medical review team.
METHOHEXITAL SODIUM is a Barbiturate Anesthetic that works by Methohexital sodium is a barbiturate that acts as a GABA-A receptor agonist, enhancing chloride conductance and causing neuronal hyperpolarization. It produces rapid sedation and anesthesia by depressing the central nervous system.. BUCET is a Barbiturate Combination Analgesic that works by Bucet is a combination of bucetin and acetaminophen. Bucetin is a para-aminophenol derivative with analgesic and antipyretic effects, possibly through inhibition of cyclooxygenase in the central nervous system. Acetaminophen inhibits COX enzymes in the brain, reducing prostaglandin synthesis and fever.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between METHOHEXITAL SODIUM and BUCET depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of METHOHEXITAL SODIUM is: Induction of anesthesia: 1-1.5 mg/kg IV bolus over 15-30 seconds. Maintenance: intermittent IV boluses of 20-40 mg every 4-7 minutes as needed.. The standard adult dose of BUCET is: Oral: 25-50 mg every 4-6 hours as needed for pain; maximum 200 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between METHOHEXITAL SODIUM and BUCET in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. METHOHEXITAL SODIUM is classified as Category C. Methohexital sodium is a barbiturate anesthetic. Use in the first trimester may be associated with a small increased risk of major malformations based on limited human data; animal. BUCET is classified as Category C. FDA Pregnancy Category D. First trimester: Increased risk of cardiac malformations and neural tube defects. Second and third trimesters: Risk of premature closure of ductus arterio. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.